Endotrophin as a risk marker of mortality and kidney complications in a type 1 diabetes cohort.

Autor:	Møller AL; Nordic Bioscience, Herlev, Denmark.; Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark., Tougaard NH; Steno Diabetes Center Copenhagen, Herlev, Denmark., Rasmussen DGK; Nordic Bioscience, Herlev, Denmark., Genovese F; Nordic Bioscience, Herlev, Denmark., Rønn PF; Steno Diabetes Center Copenhagen, Herlev, Denmark., Hansen TW; Steno Diabetes Center Copenhagen, Herlev, Denmark., Karsdal MA; Nordic Bioscience, Herlev, Denmark., Rossing P; Steno Diabetes Center Copenhagen, Herlev, Denmark.; Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
Jazyk:	angličtina
Zdroj:	Frontiers in molecular biosciences [Front Mol Biosci] 2023 Sep 01; Vol. 10, pp. 1229579. Date of Electronic Publication: 2023 Sep 01 (Print Publication: 2023).
DOI:	10.3389/fmolb.2023.1229579
Abstrakt:	Hyperglycemia triggers pathological pathways leading to fibrosis, where extracellular matrix (ECM) components are accumulated. We investigated the potential of endotrophin, a pro-fibrotic molecule generated during collagen type VI formation, as a risk marker for complications to type 1 diabetes. Endotrophin was measured in serum and urine from 1,468 persons with type 1 diabetes. Outcomes included a composite kidney endpoint, first major adverse cardiovascular event (MACE), all-cause mortality, progression of albuminuria, incident heart failure, and sight-threatening diabetic eye disease. Cox proportional hazards models adjusted for conventional risk factors were applied. A doubling of serum endotrophin was independently associated with the kidney endpoint ( n = 30/1,462; hazard ratio 3.39 [95% CI: 1.98-5.82]), all-cause mortality ( n = 93/1,468; 1.44 [1.03-2.0]), and progression of albuminuria ( n = 80/1,359; 1.82 [1.32-2.52]), but not with first MACE, heart failure, or sight-threatening diabetic eye disease after adjustment. Urinary endotrophin was not associated with any outcome after adjustment. Serum endotrophin was a risk marker for mortality and kidney complications in type 1 diabetes. Biomarkers of ECM remodeling, such as serum endotrophin, may identify persons with active pro-fibrotic processes at risk for complications in diabetes and where antifibrotic agents may reduce this risk. Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. (Copyright © 2023 Møller, Tougaard, Rasmussen, Genovese, Rønn, Hansen, Karsdal and Rossing.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu